The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 26, 2019

Filed:

Oct. 19, 2017
Applicant:

Signpath Pharma Inc., Sandy, UT (US);

Inventors:

Lawrence Helson, Quakertown, PA (US);

George M. Shopp, Boulder, CO (US);

Annie Bouchard, Stoke, CA;

Muhammed Majeed, East Windsor, NJ (US);

Assignee:

Signpath Pharma, Inc., Sandy, UT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/127 (2006.01); A61K 31/4545 (2006.01); A61K 31/12 (2006.01); A61K 31/445 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 47/24 (2006.01); A61K 31/20 (2006.01); A61K 31/23 (2006.01); A61K 31/506 (2006.01); A61K 31/683 (2006.01); A61K 31/685 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 9/127 (2013.01); A61K 9/0053 (2013.01); A61K 31/12 (2013.01); A61K 31/20 (2013.01); A61K 31/23 (2013.01); A61K 31/445 (2013.01); A61K 31/4545 (2013.01); A61K 31/506 (2013.01); A61K 31/683 (2013.01); A61K 31/685 (2013.01); A61K 45/06 (2013.01); A61K 47/24 (2013.01); G01N 33/5008 (2013.01); G01N 33/6872 (2013.01); G01N 33/6887 (2013.01); G01N 2800/32 (2013.01);
Abstract

The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a phosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, and one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.


Find Patent Forward Citations

Loading…